Guselkumab in Crohn's disease: the IL-23 race continues

TNF antagonists, anti-integrin antibodies, and antibodies against IL-12 and IL-23 are the main therapeutic options in Crohn's disease.1 Upadacitinib, an oral, small-molecule JAK antagonist was also recently approved to treat the disease.2 Although these agents represent major advances in the treatment of Crohn's disease, many patients do not respond, lose response over time, or have adverse events leading to drug discontinuation.3,4 Thus, there is a growing demand for novel therapeutic agents targeting alternative disease mechanisms.